First-line Chemotherapy in Epithelial Ovarian Cancer

被引：78

作者：

Bookman, Michael A. ^{[1
]}

机构：

[1] Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA

来源：

CLINICAL OBSTETRICS AND GYNECOLOGY | 2012年 / 55卷 / 01期

关键词：

ovarian carcinoma; carboplatin; chemotherapy; angiogenesis; dose-density; chemotherapy resistance; PHASE-III TRIAL; CARBOPLATIN PLUS PACLITAXEL; INTRAVENOUS CISPLATIN PLUS; INTERGROUP TRIAL; INTRAPERITONEAL CISPLATIN; RANDOMIZED-TRIAL; TOPOTECAN; PLATINUM; THERAPY; NO;

D O I：

10.1097/GRF.0b013e31824b45da

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Advanced-stage epithelial ovarian cancer remains a highly lethal malignancy, despite effective cytoreductive surgery and primary chemotherapy. Phase III studies have evaluated multidrug combinations, dose-dense weekly scheduling, intraperitoneal delivery, neoadjuvant chemotherapy, maintenance therapy, and targeting of angiogenesis. Incremental gains in median progression-free or overall survival have been achieved, but without an impact on overall mortality. Data support intraperitoneal cisplatin, dose-dense weekly paclitaxel, or neoadjuvant chemotherapy with interval cytoreduction in appropriate patients. Encouraging data have emerged using anti-angiogenic agents, but with questions regarding optimal timing and patient selection. The use of 3-drug combinations or maintenance chemotherapy is not supported.

引用

页码：96 / 113

页数：18

共 39 条

[1] OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) [J].

Aghajanian, C. ;

Finkler, N. J. ;

Rutherford, T. ;

Smith, D. A. ;

Yi, J. ;

Parmar, H. ;

Nycum, L. R. ;

Sovak, M. A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)

[2] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[3]

[Anonymous], 2010, Cancer Facts Figures 2010

[4] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[5] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[6] Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study [J].

Bolis, G ;

Danese, S ;

Tateo, S ;

Rabaiotti, E ;

D'Agostino, G ;

Merisio, C ;

Scarfone, G ;

Polverino, G ;

Parazzini, F .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 :74-78

[7] Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study [J].

Bolis, Giorgio ;

Scarfone, Giovanna ;

Raspagliesi, Francesco ;

Mangili, Giorgia ;

Danese, Saverio ;

Scollo, Paolo ;

Lo Russo, Domenica ;

Villa, Antonella ;

Aimone, Paola Daniela ;

Scambia, Giovanni .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (16) :2905-2912

[8] Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].

Bookman, Michael A. ;

Brady, Mark F. ;

McGuire, William P. ;

Harper, Peter G. ;

Alberts, David S. ;

Friedlander, Michael ;

Colombo, Nicoletta ;

Fowler, Jeffrey M. ;

Argenta, Peter A. ;

De Geest, Koen ;

Mutch, David G. ;

Burger, Robert A. ;

Swart, Ann Marie ;

Trimble, Edward L. ;

Accario-Winslow, Chrisann ;

Roth, Lawrence M. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425

[9] Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study [J].

Burger, R. A. ;

Brady, M. F. ;

Bookman, M. A. ;

Walker, J. L. ;

Homesley, H. D. ;

Fowler, J. ;

Monk, B. J. ;

Greer, B. E. ;

Boente, M. ;

Liang, S. X. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)

[10] Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study [J].

De Placido, S ;

Scambia, G ;

Di Vagno, G ;

Naglieri, E ;

Lombardi, AV ;

Biamonte, R ;

Marinaccio, M ;

Carteni, G ;

Manzione, L ;

Febbraro, A ;

de Matteis, A ;

Gasparini, G ;

Valerio, MR ;

Danese, S ;

Perrone, F ;

Lauria, R ;

De Laurentiis, M ;

Greggi, S ;

Gallo, C ;

Pignata, S .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2635-2642

← 1 2 3 4 →